No Data
LINE Yahoo, Furukawa Electric, etc. (additional) Rating.
Upgraded - Bullish Code Stock Name Securities Company Previous Change After ------------------------------------------------------------- <4041> Nisso Chemical Daiwa "3" "2" <9531> Tokyo Gas Mizuho "Hold" "Buy" Downgraded - Bearish Code Stock Name Securities Company Previous Change After ------------------------------------------------------------
Noil Immune --- For the fiscal year ending December 2024, the in-house drug development business and the joint pipeline will continue to be promoted.
Noil Immune Biotech <4893> announced its financial results for the fiscal year ending December 2024 on the 14th. Business revenue was 0.007 billion yen (compared to 0.316 billion yen in the previous term), operating loss was 1.069 billion yen (compared to a loss of 0.775 billion yen in the previous term), recurring loss was 0.962 billion yen (compared to a loss of 1.127 billion yen in the previous term), and net loss for the year was 0.964 billion yen (compared to a loss of 1.13 billion yen in the previous term). As for the company's business status for the fiscal year, the self-developed drug discovery business based on PRIME technology and the joint pipeline will continue.
Japan's Tertiary Industry Activity Index Slips in December
Japan Braces for BOJ to Lift Rates Sooner and Higher
Helios - For the fiscal year ending December 2024, significant revenue growth is expected, and research and development will be promoted in the fields of somatic stem cell regenerative Pharmaceuticals and iPSC regenerative Pharmaceuticals.
Helios <4593> announced its consolidated financial results (IFRS) for the fiscal year ending December 2024 on the 14th.
Japan 2024 Growth Slows Despite Stronger Fourth Quarter